Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager

Lytix Biopharma AS

OSE:LYTIX

Watchlist

Price: 7.54 NOK -1.82% Market Closed

Market Cap: 374.1m NOK

Have any thoughts about
Lytix Biopharma AS?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	Abbvie Inc NYSE:ABBV	Biotechnology
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Realty Income Corp NYSE:O	Real Estate
US	Walt Disney Co NYSE:DIS	Media
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 7.54 NOK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

LYTIX Alert

Lytix Biopharma AS

7.54

-0.14 (-1.82%)

52 Week Range	4.68 12.25
Price Target

We'll email you a reminder when the closing price reaches NOK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	Abbvie Inc NYSE:ABBV	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Realty Income Corp NYSE:O	US
	Walt Disney Co NYSE:DIS	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Lytix Biopharma AS

What unique competitive advantages
does Lytix Biopharma AS hold over its rivals?

What risks and challenges
does Lytix Biopharma AS face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Lytix Biopharma AS.

What unique competitive advantages
does Lytix Biopharma AS hold over its rivals?

What risks and challenges
does Lytix Biopharma AS face in the near future?

Summarize the latest earnings call
of Lytix Biopharma AS.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lytix Biopharma AS.

Provide P/S
for Lytix Biopharma AS.

Provide P/E
for Lytix Biopharma AS.

Provide P/OCF
for Lytix Biopharma AS.

Provide P/FCFE
for Lytix Biopharma AS.

Provide P/B
for Lytix Biopharma AS.

Provide EV/S
for Lytix Biopharma AS.

Provide EV/GP
for Lytix Biopharma AS.

Provide EV/EBITDA
for Lytix Biopharma AS.

Provide EV/EBIT
for Lytix Biopharma AS.

Provide EV/OCF
for Lytix Biopharma AS.

Provide EV/FCFF
for Lytix Biopharma AS.

Provide EV/IC
for Lytix Biopharma AS.

Show me price targets
for Lytix Biopharma AS made by professional analysts.

What are the Revenue projections
for Lytix Biopharma AS?

How accurate were the past Revenue estimates
for Lytix Biopharma AS?

What are the Net Income projections
for Lytix Biopharma AS?

How accurate were the past Net Income estimates
for Lytix Biopharma AS?

What are the EPS projections
for Lytix Biopharma AS?

How accurate were the past EPS estimates
for Lytix Biopharma AS?

What are the EBIT projections
for Lytix Biopharma AS?

How accurate were the past EBIT estimates
for Lytix Biopharma AS?

Compare the revenue forecasts
for Lytix Biopharma AS with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lytix Biopharma AS and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lytix Biopharma AS against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lytix Biopharma AS compared to its peers.

Compare the P/E ratios
of Lytix Biopharma AS against its peers.

Discuss the investment returns and shareholder value creation
comparing Lytix Biopharma AS with its peers.

Analyze the financial leverage
of Lytix Biopharma AS compared to its main competitors.

Show all profitability ratios
for Lytix Biopharma AS.

Provide ROE
for Lytix Biopharma AS.

Provide ROA
for Lytix Biopharma AS.

Provide ROIC
for Lytix Biopharma AS.

Provide ROCE
for Lytix Biopharma AS.

Provide Gross Margin
for Lytix Biopharma AS.

Provide Operating Margin
for Lytix Biopharma AS.

Provide Net Margin
for Lytix Biopharma AS.

Provide FCF Margin
for Lytix Biopharma AS.

Show all solvency ratios
for Lytix Biopharma AS.

Provide D/E Ratio
for Lytix Biopharma AS.

Provide D/A Ratio
for Lytix Biopharma AS.

Provide Interest Coverage Ratio
for Lytix Biopharma AS.

Provide Altman Z-Score Ratio
for Lytix Biopharma AS.

Provide Quick Ratio
for Lytix Biopharma AS.

Provide Current Ratio
for Lytix Biopharma AS.

Provide Cash Ratio
for Lytix Biopharma AS.

What is the historical Revenue growth
over the last 5 years for Lytix Biopharma AS?

What is the historical Net Income growth
over the last 5 years for Lytix Biopharma AS?

What is the current Free Cash Flow
of Lytix Biopharma AS?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lytix Biopharma AS.

LYTIX

Income Statement

Income from Continuing Operations

Lytix Biopharma AS
Income from Continuing Operations

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

Adjust for Inflation

Lytix Biopharma AS
Income from Continuing Operations Peer Comparison

Comparables:

HBC

BGBIO

AZT

NYKD

TRMED

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company		Income from Continuing Operations	CAGR 3Y	CAGR 5Y	CAGR 10Y
L	Lytix Biopharma AS OSE:LYTIX	Income from Continuing Operations -kr87.9m	CAGR 3-Years -28%	CAGR 5-Years -7%	CAGR 10-Years N/A
	Hofseth Biocare ASA OSE:HBC	Income from Continuing Operations -kr97.9m	CAGR 3-Years 4%	CAGR 5-Years -3%	CAGR 10-Years -9%
B	Bergenbio ASA OSE:BGBIO	Income from Continuing Operations -kr154.5m	CAGR 3-Years 19%	CAGR 5-Years 3%	CAGR 10-Years N/A
	Arcticzymes Technologies ASA OSE:AZT	Income from Continuing Operations kr16.9m	CAGR 3-Years -42%	CAGR 5-Years N/A	CAGR 10-Years N/A
N	Nykode Therapeutics ASA OSE:NYKD	Income from Continuing Operations -$39.7m	CAGR 3-Years N/A	CAGR 5-Years -45%	CAGR 10-Years N/A
T	Thor Medical ASA OSE:TRMED	Income from Continuing Operations -kr32.1m	CAGR 3-Years 57%	CAGR 5-Years 38%	CAGR 10-Years -7%

What is Lytix Biopharma AS's Income from Continuing Operations?

Income from Continuing Operations
-87.9m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Income from Continuing Operations amounts to -87.9m NOK.

What is Lytix Biopharma AS's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-7%

Over the last year, the Income from Continuing Operations growth was -57%. The average annual Income from Continuing Operations growth rates for Lytix Biopharma AS have been -28% over the past three years , -7% over the past five years .

Lytix Biopharma AS
OSE:LYTIX

Lytix Biopharma AS
Income from Continuing Operations

Lytix Biopharma AS
Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

See Also

What is Lytix Biopharma AS's Income from Continuing Operations?

Income from Continuing Operations
-87.9m NOK

What is Lytix Biopharma AS's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-7%

Company

Help

Tools

Stocks

Lytix Biopharma AS OSE:LYTIX

Lytix Biopharma AS Income from Continuing Operations

Lytix Biopharma AS Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis Latest Figures & CAGR of Competitors

See Also

What is Lytix Biopharma AS's Income from Continuing Operations? Income from Continuing Operations -87.9m NOK

What is Lytix Biopharma AS's Income from Continuing Operations growth rate? Income from Continuing Operations CAGR 5Y -7%

Company

Help

Tools

Stocks

Lytix Biopharma AS
OSE:LYTIX

Lytix Biopharma AS
Income from Continuing Operations

Lytix Biopharma AS
Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

What is Lytix Biopharma AS's Income from Continuing Operations?

Income from Continuing Operations
-87.9m NOK

What is Lytix Biopharma AS's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-7%